Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of misleading statements and failure to disclose critical information regarding its prostate cancer therapeutic candidates and supply chain issues [2][5]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses in Telix between February 21, 2025, and August 28, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Telix, with a deadline of January 9, 2026, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [8]. Group 2: Allegations Against Telix - The complaint alleges that Telix and its executives violated federal securities laws by making false and misleading statements regarding the progress of prostate cancer therapeutic candidates and the quality of its supply chain [5]. - Following the announcement of a subpoena from the U.S. Securities and Exchange Commission, Telix's American Depositary Shares (ADSs) fell more than 13% over two trading sessions [6]. - On August 28, 2025, Telix disclosed receiving a Complete Response Letter from the FDA, which led to a further decline of over 21% in the price of its ADSs [7].
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals